| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico. .png)
|
|
Today’s Big NewsJan 29, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Fraiser Kansteiner Despite finishing strong in 2024, Teva’s cautious approach to the new year appears to have investors spooked. The company's subdued guidance likely explains the performance of Teva’s stock, which plunged 13% on Wednesday. |
|
|
|
By Conor Hale Paragon 28’s catalog spans products for fracture and trauma fixation procedures in addition to deformity corrections and joint replacements. |
By Nick Paul Taylor I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline reprioritization. |
By Andrea Park A squadron of senators is once again putting forward a proposal to boost price transparency in direct-to-consumer pharmaceutical advertising. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By James Waldron The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech—but it’s been bad news for some of its staff. The company is now laying off 40% of its employees as it gears up for registrational studies in ovarian cancer. |
By Kevin Dunleavy The Department of Health and Human Services and the Department of Veterans Affairs have filed an objection to Johnson & Johnson's attempt to resolve its talc litigation through Chapter 11 bankruptcy. The agencies argue that J&J’s plan is in “violation of the Bankruptcy Code and federal law.” |
By Conor Hale Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to divest its international enterprises in the months to come. |
By Nick Paul Taylor The Partnership to Fight Infectious Disease has put out a timely notice about support for vaccines. Forty-five minutes before Robert F. Kennedy Jr. sat down for his first grilling by the Senate, the nonprofit shared survey data showing 74% of U.S. voters want FDA-approved vaccines to be widely available. |
By Kevin Dunleavy So far this month, companies in the biopharma industry have raised prices on more than 930 products but the increases have largely been modest, averaging 4%. |
By James Waldron Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the data close to its chest for now. |
By Andrea Park Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. |
By Zoey Becker The U.S. State Department is allowing the supply of critical drugs to continue despite an executive order temporarily freezing foreign aid for 90 days. |
By Darren Incorvaia Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in patients with amyotrophic lateral sclerosis. Now, a new study has not only confirmed that sleep disruption is a symptom of ALS but has identified two potential hormone therapies that could treat it. |
By Darren Incorvaia Pregnancy comes with unique health risks and considerations, but pregnant people also continue to experience the same health problems that nonpregnant people do. Despite this, a new study has found that fewer than 1% of randomized controlled trials in the U.S. include pregnant participants. |
By Nick Paul Taylor Want the eyeballs of people with obesity? Think TV. That is a takeaway from a CMI survey that suggests the fight for attention will be waged on traditional marketing battlegrounds, with TV emerging as the best way to reach people with obesity and Facebook still reigning supreme in the social media space. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
